Filter the drugs by the phase of research, how they help and the responsive mutations.
Cystic fibrosis is a genetic disease caused by mutations in the CFTR gene. Browse the
database of
drugs treating specific mutations compiled by the AIM tool.
Drug | Marketed as | Description | Phase of research | How it helps |
---|---|---|---|---|
NB30 | Aminoglycoside capable of translational readthrough |
Pre-clinical | Restore CFTR Function | |
NB54 | Aminoglycoside capable of translational readthrough |
Pre-clinical | Restore CFTR Function | |
NCI118208 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
NCI130813 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
NCI407882 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
NCI73100 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
NS004 | Enhances CFTR activity |
Pre-clinical | Restore CFTR Function | |
Nitric oxide | Gas with antimicrobial properties |
Phase Two Clinical Trial | Anti-Infective | |
OligoG | Decreases the thickness of mucus in the lungs |
Phase Two Clinical Trial | Mucociliary Clearance | |
Omalizumab | Xolair® | Treats CF-related allergic bronchopulmonary aspergillosis |
FDA-/EMA-approved for Other Purpose | Nutritional-GI-Other |